Immunosuppressive therapy for Myelodysplastic syndromes

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3184-3189

  Dobbelstein, Christiane ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Aplastic anemia; Apoptosis; ATG; HLA DR15; Immunosuppression; Lymphoglobulin; Myelodysplastic syndrome; T cell mediation; Thymoglobulin; TNF

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; ETANERCEPT; GROWTH FACTOR; IMMUNOGLOBULIN; INFLIXIMAB; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY;

ALLOTRANSPLANTATION; APLASTIC ANEMIA; APOPTOSIS; BONE MARROW CELL; BONE MARROW DEPRESSION; BRADYCARDIA; COLONY FORMING UNIT GM; CONSTIPATION; CYTOPENIA; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DROWSINESS; DRUG ERUPTION; DRUG MEGADOSE; EMBRYOPATHY; HEMATOPOIESIS; HIGH RISK POPULATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW RISK POPULATION; MYELODYSPLASTIC SYNDROME; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOEMBOLISM;

EID: 84862538596     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023184     Document Type: Review

References (64)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-51.
2. Nimer SD. Myelodysplastic syndromes. Blood 2008; 111: 4841-4851.
3. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-85.
4. Schiffer CA. Myelodysplasia: the good, the fair and the ugly. Best Pract Res Clin Haematol 2007; 20 (1): 49-55.
5. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113: 6296-6303.
6. Raza A, Grezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86(1): 268-276.
7. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88(11): 4275-87.
8. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11(6): 839-45.
9. Huh YO, Jilani I, Estey E et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia 2002; 16: 2249-2252.
10. Parker JE, Mufti GJ. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma 2000; 40 (1-2): 1-24.
11. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-188.
12. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 6 (12): 1268-72.
13. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R. Over-expression of tumor-necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005; 75: 485-491.
14. Sashida G, Ohyashiki JH, Nakajima A, et al. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 2003; 9(4): 1489-96.
15. Rollison DE, Epling-Burnette PK, Park JY, et al. Telomere length in myelodysplastic syndromes. Leuk Lymphoma 2011; 52(8): 1528-1536.
16. Kurotaki H, Tsushima Y, Nagai K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 1999; 102(3): 115-123.
17. Francis GE, Wing MA, Miller EJ, Berney JJ, Wonke B, Hoffbrand AV. Use of bone-marrow culture in prediction of acute leukaemic transformation in preleukaemia. Lancet 1983; 1(8339): 1409-12.
18. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 2004; 34(10): 690-700.
19. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986; 63(1): 143-7.
20. Hamblin TJ. Myelodysplasia. Br J Hosp Med 1987; 38: 558-561.
21. Billström R, Johansson H, Johansson B, Mitelman F. Immunemediated complications in patients with myelodysplastic syndromes--clinical and cytogenetic features. Eur J Haematol 1995; 55(1): 42-8.
22. Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 639-645.
23. Chamuleau MED, Westers TM, van Dreunen L, et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 2009; 94: 496-506.
24. Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009; 94(4): 449-51.
25. Maciejewski JP, Risitano AM, Sloand EM, et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor 8p75) - Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002; 117(1): 119-26.
26. Stasi R, Amadori S. Infliximab chimeric anti-tumor necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 2002; 116 (2): 334-7.
27. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046.
28. Molldrem JJ, Ziang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102(5): 1314-22.
29. Tichelli A, Gratwohl A Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 1988; 68(1): 139-40.
30. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
31. Molldrem JJ, Leifer E, Bahceci E et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
32. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with low-risk myelodysplasia. Br J Haematol 2003; 120: 679-684.
33. Yazji S, Giles FJ, Tsimberidou AM et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17: 2101-2106.
34. Steensma DP, Dispenzieri A, Breanndan Moore S, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101: 2156-2158.
35. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-309.
36. Stadler M, Germing U, Kliche KO et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460-465.
37. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-438.
38. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk nonsideroblastic myelodysplastic syndromes. Haematologica 2006; 91: 667-670.
39. Sloand EM, Wu CO, Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26(15): 2505-11.
40. Aivado M, Rong A, Stadler M, et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002; 68(4): 210-6.
41. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to antithymocyte globulin. Leukemia 2007; 21,1436-1441.
42. Passweg JR, Giagounidis AAN, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care - SAKK 33/99. J Clin Oncol 2011; 29: 303-309.
43. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75(5): 657-62.
44. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR 15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 1570-1574.
45. Bagby GC Jr, Gabourel JD, Linman JW. Glucocorticoid therapy in the preleukemic syndrome (hematopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Intern Med 1980; 92: 55-58.
46. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS. Biological and immunological characterization of ATG and ALG. Blood 1986; 68: 712-719.
47. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025-3027.
48. Kim H, Min YJ, Baek JH, et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009 Feb; 33(2): 222-31.
49. Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010; 28: 5166-5173.
50. Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002; 16: 162-164.
51. Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR: Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 2002; 26(8): 721-4.
52. Stasi R, Amadori S, Newland AC, Provan D. Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma 2005; 46(4): 509-16.
53. Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011; 305(8): 814-819.
54. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its ImiD derivatives as anticancer agents. Nature Reviews 2004; 4: 314-322.
55. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic sindrome and acute myeloid leukemia. Cancer 2008; 113(7): 1596-604.
56. Tamburini J, Elie C, Park S, et al. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res 2009; 33(4): 547-50.
57. Zheng WL, Zhang GS, Xu YX, Shen JK, Dai CW, Pei MF. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leuk Res 2008; 32(2): 251-4.
58. Raza A, Lisak L, Billmeier J, et al. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. Leuk Lymphoma 2006; 47(3): 433-40.
59. Bouscary D, Legros L, Tulliez M, et al. A non-randomised doseescalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies. Br J Haematol 2005; 131(5): 609-18.
60. Invernizzi R, Travaglino E, De Amici M, et al. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk Res 2005; 29(6): 641-7.
61. Steurer M, Sudmeier I, Stauder R, Gastl G. Thrombembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003; 121(1): 101-3.
62. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352 (6): 549-57.
63. List A, Dewald G, Bennett J et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
64. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111(1): 86-93.